Cargando…
Lifetime medical costs attributable to sickle cell disease among nonelderly individuals with commercial insurance
Sickle cell disease (SCD) is a severe monogenic disease associated with high morbidity, mortality, and a disproportionate burden on Black and Hispanic communities. Our objective was to estimate the total healthcare costs and out-of-pocket (OOP) costs attributable to SCD among commercially insured in...
Autores principales: | Johnson, Kate M., Jiao, Boshen, Ramsey, Scott D., Bender, M. A., Devine, Beth, Basu, Anirban |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898623/ https://www.ncbi.nlm.nih.gov/pubmed/35575558 http://dx.doi.org/10.1182/bloodadvances.2021006281 |
Ejemplares similares
-
Prevalence of comorbidities associated with sickle cell disease among non-elderly individuals with commercial insurance–A retrospective cohort study
por: Ramsey, Scott D., et al.
Publicado: (2022) -
Development of a conceptual model for evaluating new non-curative and curative therapies for sickle cell disease
por: Johnson, Kate M., et al.
Publicado: (2022) -
Long-term survival with sickle cell disease: a nationwide cohort study of Medicare and Medicaid beneficiaries
por: Jiao, Boshen, et al.
Publicado: (2023) -
Medical and Non-medical Costs of Sickle Cell Disease and Treatments from a US Perspective: A Systematic Review and Landscape Analysis
por: Baldwin, Zachary, et al.
Publicado: (2022) -
The economic burden of NIPC and BOS following allogeneic HSCT in patients with commercial insurance in the United States
por: Sacks, Naomi C., et al.
Publicado: (2022)